IRF3 Activation in Mast Cells Promotes FcεRI-Mediated Allergic Inflammation
- PMID: 37296614
- PMCID: PMC10252328
- DOI: 10.3390/cells12111493
IRF3 Activation in Mast Cells Promotes FcεRI-Mediated Allergic Inflammation
Abstract
(1) Background: This study aims to elucidate a novel non-transcriptional action of IRF3 in addition to its role as a transcription factor in mast cell activation and associated allergic inflammation; (2) Methods: For in vitro experiments, mouse bone-marrow-derived mast cells (mBMMCs) and a rat basophilic leukemia cell line (RBL-2H3) were used for investigating the underlying mechanism of IRF3 in mast-cell-mediated allergic inflammation. For in vivo experiments, wild-type and Irf3 knockout mice were used for evaluating IgE-mediated local and systemic anaphylaxis; (3) Results: Passive cutaneous anaphylaxis (PCA)-induced tissues showed highly increased IRF3 activity. In addition, the activation of IRF3 was observed in DNP-HSA-treated mast cells. Phosphorylated IRF3 by DNP-HSA was spatially co-localized with tryptase according to the mast cell activation process, and FcεRI-mediated signaling pathways directly regulated that activity. The alteration of IRF3 affected the production of granule contents in the mast cells and the anaphylaxis responses, including PCA- and ovalbumin-induced active systemic anaphylaxis. Furthermore, IRF3 influenced the post-translational processing of histidine decarboxylase (HDC), which is required for granule maturation; and (4) Conclusion: Through this study, we demonstrated the novel function of IRF3 as an important factor inducing mast cell activation and as an upstream molecule for HDC activity.
Keywords: allergic inflammation; histamine; histidine decarboxylase; interferon regulatory factor 3; mast cells.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Davallia mariesii Moore Improves FcεRI-Mediated Allergic Responses in the Rat Basophilic Leukemia Mast Cell Line RBL-2H3 and Passive Cutaneous Anaphylaxis in Mice.Mediators Inflamm. 2017;2017:8701650. doi: 10.1155/2017/8701650. Epub 2017 Oct 19. Mediators Inflamm. 2017. PMID: 29200667 Free PMC article.
-
SG-SP1 Suppresses Mast Cell-Mediated Allergic Inflammation via Inhibition of FcεRI Signaling.Front Immunol. 2020 Jan 28;11:50. doi: 10.3389/fimmu.2020.00050. eCollection 2020. Front Immunol. 2020. PMID: 32063904 Free PMC article.
-
Plant-Derived Molecule 4-Methylumbelliferone Suppresses FcεRI-Mediated Mast Cell Activation and Allergic Inflammation.Molecules. 2022 Feb 27;27(5):1577. doi: 10.3390/molecules27051577. Molecules. 2022. PMID: 35268679 Free PMC article.
-
Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation.Arch Immunol Ther Exp (Warsz). 2008 Nov-Dec;56(6):385-99. doi: 10.1007/s00005-008-0041-2. Epub 2008 Dec 1. Arch Immunol Ther Exp (Warsz). 2008. PMID: 19082920 Review.
-
Mast cell activation syndrome: An up-to-date review of literature.World J Clin Pediatr. 2024 Jun 9;13(2):92813. doi: 10.5409/wjcp.v13.i2.92813. eCollection 2024 Jun 9. World J Clin Pediatr. 2024. PMID: 38948000 Free PMC article. Review.
Cited by
-
Aspalathin, a Primary Rooibos Flavonoid, Alleviates Mast Cell-Mediated Allergic Inflammation by the Inhibition of FcεRI Signaling Pathway.Inflammation. 2024 May 23. doi: 10.1007/s10753-024-02034-1. Online ahead of print. Inflammation. 2024. PMID: 38777857
References
-
- Doll R.J., Joseph N.I., McGarry D., Jhaveri D., Sher T., Hostoffer R. Epidemiology of allergic diseases. Allergy Asthma. 2019:31–51. doi: 10.1007/978-3-030-05147-1_2. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical